Quinolinic acid discovery reveals new prostate cancer treatment pathway

A new study has uncovered a biochemical pathway involving quinolinic acid that could change how prostate cancer is treated. Researchers found that this metabolite plays a key role in fueling cancer cell growth and resistance to therapy. The discovery offers fresh hope for patients facing the disease, which remains a leading health concern for men globally. The research, led by Zhang and colleagues, identified quinolinic acid (QA) as a critical modulator in prostate cancer. Produced by the enzyme HAAO, QA enhances androgen receptor (AR) signalling through an FDPS-dependent mechanism. This process boosts cancer cell survival and contributes to the development of treatment resistance.

HAAO expression was shown to be significantly higher in prostate cancer tissues, particularly in advanced stages. The study linked elevated HAAO levels to poorer patient outcomes. Using transcriptomics, metabolomics, and functional assays, the team confirmed QA’s role in driving FDPS expression and activity.

The findings suggest that targeting QA synthesis, or combining HAAO inhibitors with existing anti-androgen drugs like enzalutamide, could delay or prevent resistance. Modulating QA levels may also sensitise cancer cells to combination therapies, opening a new therapeutic window. The study highlights the potential of metabolic interventions to improve prostate cancer treatment. By disrupting the QA-driven pathway, clinicians may enhance the effectiveness of hormonal therapies. Further research into metabolic byproducts and their signalling roles could lead to more refined and effective treatment strategies.